#PathCR - Twitter Hashtag

Excellence in Oncology Care - EIOC @EiocOncology

4 months ago

Update on db11. It’s not only about achieving a pcr. Low rcb also makes a difference. #ESMOBreast26 #HER2Positive #BreastCancer #PathCR @OncoAlert

EiocOncology's tweet photo. Update on db11. It’s not only about achieving a pcr. Low rcb also makes a difference.

#ESMOBreast26 #HER2Positive #BreastCancer #PathCR @OncoAlert https://t.co/AIYylnbft4

0

3

1

0

210

Tatiana Prowell, MD @tmprowell

about 1 year ago

@FordePatrick @NEJM @VirginiaCalvo6 @gecp_org @tcddublin @cancertrials_ie @CancerInstIRE @MARIANOPROVENCI @DoctorJSpicer Proud of you, @FordePatrick 😊 cc @hopkinskimmel #pathCR #lcsm #OncTwitter

tmprowell's tweet photo. @FordePatrick @NEJM @VirginiaCalvo6 @gecp_org @tcddublin @cancertrials_ie @CancerInstIRE @MARIANOPROVENCI @DoctorJSpicer Proud of you, @FordePatrick 😊

cc @hopkinskimmel
#pathCR #lcsm #OncTwitter https://t.co/EzwOzRnAf7

1

5

2

0

763

Prof Ananya💙 @achoud72.bsky.social @achoud72

almost 4 years ago

Particularly interesting is the similar #pathCR rate for chemo or chemoIO combinations - second photo below - courtesy @MattMilowsky - is #pathCR a poor endpoint for systemic Rx or is there really no difference? We wait to see🤔 @tompowles1 #BLADDR22 @mirrorsmed

Petros Grivas @PGrivasMDPhD

almost 4 years ago

Stellar talks by @tompowles1 @Uromigos on systemic therapies in urothelial Ca. Several peri-op trials evaluating chemo/IO or EV/IO have the potential to change practice. The role of ctDNA very promising! @OncoAlert @sonpavde @achoud72 @b_szabados @mirrorsmed @mtsiatas @mkmoutafi

PGrivasMDPhD's tweet photo. Stellar talks by @tompowles1 @Uromigos on systemic therapies in urothelial Ca. Several peri-op trials evaluating chemo/IO or EV/IO have the potential to change practice. The role of ctDNA very promising! @OncoAlert @sonpavde @achoud72 @b_szabados @mirrorsmed @mtsiatas @mkmoutafi https://t.co/Attjsm5Ebn

0

27

14

2

0

1

7

2

0

Sheheryar Kabraji @SKabrajiMD

about 4 years ago

@PTarantinoMD @MyriamChalabi #bcsm researchers have a lot of experience with #PathCR and outcomes but largely after chemo. Will be watching closely to see trends after #ICI alone in other cancers

0

2

0

Anchit Khanna MD PhD @your_Lifesaver

almost 7 years ago

#NeoAdjuvantTherapy in aggressive early stage #breastCancer such as #TripleNegativeBreastCancer provides a)vital time 4 #CancerPatients to absorb all the info 4 making decisions b)the much needed positive mindset when 1 achieves a response (#pathCR) #BreastCancerAwarenessMonth

0

3

0

Omid Hamid MD

@OmidHamidMD

over 7 years ago

Those who didn’t stay late for the #melanoma orals @asco #asco19 missed the most important information #adjuvant and #neoadjuvant #immunoOncology that is relevant to all tumors, keys to second line therapy and importance of #pathCR @ATarhiniMDPhD @amenzies9

OmidHamidMD's tweet photo. Those who didn’t stay late for the #melanoma orals @asco #asco19 missed the most important information #adjuvant and #neoadjuvant #immunoOncology that is relevant to all tumors, keys to second line therapy and importance of #pathCR @ATarhiniMDPhD @amenzies9 https://t.co/lkKotoXK68

1

13

4

1

0

Top Tweets for #PathCR

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users